COENZYME Q10 AND LISINOPRIL- Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies

Frequently Asked Questions (FAQs) about this research:

 

What stage is this research?

  • This clinical trial is closed to new enrollment, and all participant data has been collected.The study added an extension study that collected longer-term cardiac data on a subset of participants in the parent study. During the coming months, the study team is locking the data and starting analysis on the dataset.

 

What is the goal or purpose of this study?

  • This is a clinical trial to test a medication used for the heart, called lisinopril (an angiotensin converting Glossary Link enzyme (ACE) inhibitor) and supplement called Coenzyme Q10, to ameliorate the decline in cardiac muscle functions that occurs in muscular dystrophies. The goal of this study is to determine if Coenzyme Q10 alone, Lisinopril alone, or a combination of Coenzyme Q10 and Lisinopril is more effective at delaying the onset of cardiac symptoms in patients with Duchenne, Becker, or Limb Girdle muscular dystrophy. 

 

Who is funding this study?

  • This study is funded by the Department of Defense (DOD).

 

Who was eligible to participate in this study?

  • Participants must have a confirmed genetic diagnosis of Duchenne, Becker, or Limb Girdle muscular dystrophy (certain type 2 only), be 8 years of age or older, and have no clinical cardiac symptoms with a normal left ventricular fractional shortening (>28%) on echocardiogram.

 

Where does this study take place?

  • This study enrolled participants at select Cooperative International Neuromuscular Research Group (CINRG) network sites. These sites include: Children’s National Medical Center, Washington, DC; Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL; Carolinas Medical Center, Charlotte, NC; University of Pittsburgh, Pittsburgh, PA; University of Tennessee, Memphis, TN; National Center of Neurology and Psychiatry, Tokyo, Japan; and Alberta Children’s Hospital, Calgary, Alberta, Canada.  

 

When is the study anticipated to be completed and results available?

  • The clinical trial and the extension anticipate having results available in late 2017.

 

Where can I learn more about this study?

 

(Updated 4/19/2017)